Announcement • Jun 03
China Regenerative Medicine International Limited, Annual General Meeting, Jun 26, 2026 China Regenerative Medicine International Limited, Annual General Meeting, Jun 26, 2026, at 11:00 China Standard Time. Location: suite 2310-2318, miramar tower, 132 nathan road, tsim sha tsui, kowloon, Hong Kong New Risk • May 05
New major risk - Financial position The company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 14% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (14% operating cash flow to total debt). High level of non-cash earnings (37% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (HK$115.6m market cap, or US$14.8m). Reported Earnings • Mar 28
Full year 2025 earnings released: EPS: HK$0.091 (vs HK$0.058 in FY 2024) Full year 2025 results: EPS: HK$0.091 (up from HK$0.058 in FY 2024). Revenue: HK$72.1m (down 21% from FY 2024). Net income: HK$27.5m (up 55% from FY 2024). Profit margin: 38% (up from 20% in FY 2024). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings. New Risk • Mar 19
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: HK$73.9m (US$9.44m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (5.8% operating cash flow to total debt). Market cap is less than US$10m (HK$73.9m market cap, or US$9.44m). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Announcement • Mar 16
China Regenerative Medicine International Limited to Report Fiscal Year 2025 Results on Mar 27, 2026 China Regenerative Medicine International Limited announced that they will report fiscal year 2025 results at 12:30 PM, China Standard Time on Mar 27, 2026 New Risk • Mar 10
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (5.8% operating cash flow to total debt). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (HK$101.9m market cap, or US$13.0m). Reported Earnings • Aug 25
First half 2025 earnings released: EPS: HK$0.015 (vs HK$0.069 in 1H 2024) First half 2025 results: EPS: HK$0.015 (down from HK$0.069 in 1H 2024). Revenue: HK$27.4m (down 54% from 1H 2024). Net income: HK$4.61m (down 78% from 1H 2024). Profit margin: 17% (down from 35% in 1H 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings. Announcement • Aug 12
China Regenerative Medicine International Limited to Report First Half, 2025 Results on Aug 22, 2025 China Regenerative Medicine International Limited announced that they will report first half, 2025 results on Aug 22, 2025 Announcement • Jun 30
China Regenerative Medicine International Limited Announces Board and Committee Changes, Effective June 30, 2025 The board of directors of China Regenerative Medicine International Limited announced that Dr. Liu Ming (‘Dr. Liu’) has resigned as an independent non-executive Director with effect from 30 June 2025 due to his personal commitment. Dr. Liu has ceased to be a member of the audit committee of the Company, the Chairman of each of the nomination committee of the Company and the remuneration committee of the Company upon his resignation as an independent non-executive Director. Upon his resignation, Dr. Liu would no longer hold any position in the Group. Mr. Zhou Xudong (‘Mr. Zhou’) has been appointed as an independent non-executive Director, a member of the Audit Committee, the Chairman of each of the Remuneration Committee and Nomination Committee with effect from 30 June 2025, in place of Dr. Liu. Mr. Zhou Xudong, aged 58, a second-grade solicitor with over 30 years of legal practice in the People's Republic of China, has extensive experience in corporate areas and arbitration. Mr. Zhou has currently served as an executive director of the Jiangsu Case Law Society, and a vice president of the Changzhou Arbitration Association. Since December 2003, Mr. Zhou has been serving as the director and successively the partner of Jiangsu Dongsheng Law Firm. Further, Mr. Zhou has been appointed as an independent non-executive director at each of Jiangsu Huayang Intelligent Equipment Co. Ltd. since June 2020, Jiangsu Changyou Environmental Protection Technology Co. Ltd. since December 2020, and Terrence Energy Equipment Co. Ltd. since October 2021. Mr. Zhou graduated from Nanjing Normal University with a Bachelor's degree in Laws in 1989, and a Master's degree in Business Administration from Tianjin University in 1997. From 1989 to 1998, Mr. Zhou served as a law lecturer at Changzhou Radio and Television University (now known as Changzhou Open University), while concurrently practising as a part-time lawyer at Changzhou No. 6 Law Firm from 1994 to 1998. From 1998 to 2003, Mr. Zhou was a director of Changzhou Dongzhen Law Firm. From 2012 to 2022, Mr. Zhou was appointed as the vice president of Zhonglou District Committee of the Political Consultative Conference in Changzhou, while Mr. Zhou was concurrently appointed as an independent non-executive director of Jiangsu Guomao Reducer Co. Ltd. from 2016 to 2022. The Board announced that Ms. Chan Lok Tung (‘Ms. Chan’) has been appointed as the company secretary of the Company; an authorised representative of the Company and an authorised representative for the purpose of accepting service of process and notices on behalf of the Company in Hong Kong with effect from 30 June 2025. Ms. Chan is a manager of Universe Corporate Services Limited. She has over 6 years of experience in handling listed company secretarial and compliance related matters. Ms. Chan obtained a Bachelor's degree of Business Administration (Honours) in Accountancy at the City University of Hong Kong in July 2016. She is an associate member of both The Hong Kong Chartered Governance Institute (formerly known as The Hong Kong Institute of Chartered Secretaries) and The Chartered Governance Institute (formerly known as The Institute of Chartered Secretaries and Administrators). Ms. Chan satisfies the qualification requirements for company secretary under Rule 5.14 of the GEM Listing Rules. Announcement • Jun 03
China Regenerative Medicine International Limited, Annual General Meeting, Jun 27, 2025 China Regenerative Medicine International Limited, Annual General Meeting, Jun 27, 2025, at 11:00 China Standard Time. Location: suite 2310-2318, miramar tower, 132 nathan road, tsim sha tsui, kowloon, Hong Kong New Risk • May 08
New minor risk - Financial position The company has a high level of debt. Net debt to equity ratio: 105% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (16% average weekly change). Minor Risks High level of debt (105% net debt to equity). Market cap is less than US$100m (HK$121.7m market cap, or US$15.7m). Buy Or Sell Opportunity • Apr 28
Now 22% undervalued Over the last 90 days, the stock has risen 45% to HK$0.40. The fair value is estimated to be HK$0.51, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 65% over the last 3 years. Meanwhile, the company has become profitable. Buy Or Sell Opportunity • Apr 10
Now 31% undervalued Over the last 90 days, the stock has risen 20% to HK$0.36. The fair value is estimated to be HK$0.52, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 65% over the last 3 years. Meanwhile, the company has become profitable. Reported Earnings • Mar 30
Full year 2024 earnings released: EPS: HK$0.058 (vs HK$0.38 loss in FY 2023) Full year 2024 results: EPS: HK$0.058 (up from HK$0.38 loss in FY 2023). Revenue: HK$90.6m (up 30% from FY 2023). Net income: HK$17.8m (up HK$125.5m from FY 2023). Profit margin: 20% (up from net loss in FY 2023). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 48 percentage points per year, which is a significant difference in performance. Announcement • Mar 15
China Regenerative Medicine International Limited to Report Fiscal Year 2024 Results on Mar 28, 2025 China Regenerative Medicine International Limited announced that they will report fiscal year 2024 results on Mar 28, 2025 New Risk • Mar 11
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (HK$82.1m market cap, or US$10.6m). New Risk • Feb 06
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: HK$77.6m (US$9.96m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Market cap is less than US$10m (HK$77.6m market cap, or US$9.96m). Board Change • Jan 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. Independent Non-Executive Director Man Fai Leung was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Aug 26
First half 2024 earnings released: EPS: HK$0.055 (vs HK$0.045 in 1H 2023) First half 2024 results: EPS: HK$0.055 (up from HK$0.045 in 1H 2023). Revenue: HK$59.8m (down 40% from 1H 2023). Net income: HK$16.8m (up 32% from 1H 2023). Profit margin: 28% (up from 13% in 1H 2023). The increase in margin was driven by lower expenses. Announcement • Aug 21
China Regenerative Medicine International Limited Announces Resignation of Tsang Ho Yin as A Non-Executive Director The board of directors of China Regenerative Medicine International Limited announced that Mr. Tsang Ho Yin has tendered his resignation as a non-executive Director of the Company with effect from 20 August 2024 as he would like to devote more time and attention to his other personal business engagements. Upon Mr. Tsang resignation, Mr. Tsang will cease to act as a member of the remuneration committee of the Board. Announcement • Aug 10
China Regenerative Medicine International Limited to Report First Half, 2024 Results on Aug 23, 2024 China Regenerative Medicine International Limited announced that they will report first half, 2024 results on Aug 23, 2024 Announcement • Jun 06
China Regenerative Medicine International Limited, Annual General Meeting, Jun 28, 2024 China Regenerative Medicine International Limited, Annual General Meeting, Jun 28, 2024, at 11:00 China Standard Time. Location: suite 2310-2318, miramar tower, 132 nathan road, tsim sha tsui, kowloon, Hong Kong Reported Earnings • Apr 03
Full year 2023 earnings released: HK$0.38 loss per share (vs HK$0.016 profit in FY 2022) Full year 2023 results: HK$0.38 loss per share (down from HK$0.016 profit in FY 2022). Revenue: HK$69.5m (down 70% from FY 2022). Net loss: HK$107.7m (down HK$112.3m from profit in FY 2022). Announcement • Mar 19
China Regenerative Medicine International Limited to Report Fiscal Year 2023 Results on Mar 28, 2024 China Regenerative Medicine International Limited announced that they will report fiscal year 2023 results on Mar 28, 2024 New Risk • Dec 27
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (19% average weekly change). Minor Risks Profit margins are more than 30% lower than last year (0.4% net profit margin). Shareholders have been diluted in the past year (6.6% increase in shares outstanding). Market cap is less than US$100m (HK$182.6m market cap, or US$23.4m). Reported Earnings • Nov 16
Third quarter 2023 earnings released: HK$0.021 loss per share (vs HK$0.029 profit in 3Q 2022) Third quarter 2023 results: HK$0.021 loss per share (down from HK$0.029 profit in 3Q 2022). Revenue: HK$12.0m (down 84% from 3Q 2022). Net loss: HK$6.09m (down 173% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 121% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings. New Risk • Nov 16
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 42% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.4% net profit margin). Market cap is less than US$100m (HK$137.0m market cap, or US$17.6m). Announcement • Nov 02
China Regenerative Medicine International Limited to Report Q3, 2023 Results on Nov 14, 2023 China Regenerative Medicine International Limited announced that they will report Q3, 2023 results on Nov 14, 2023 New Risk • Aug 20
New major risk - Financial position The company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (15% average weekly change). Minor Risks Profit margins are more than 30% lower than last year (6.2% net profit margin). Market cap is less than US$100m (HK$256.9m market cap, or US$32.8m). Reported Earnings • Aug 16
Second quarter 2023 earnings released: EPS: HK$0.004 (vs HK$0 in 2Q 2022) Second quarter 2023 results: EPS: HK$0.004 (up from HK$0 in 2Q 2022). Revenue: HK$46.0m (up 34% from 2Q 2022). Net income: HK$11.2m (up HK$10.1m from 2Q 2022). Profit margin: 24% (up from 3.2% in 2Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 127% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings. Announcement • Aug 03
China Regenerative Medicine International Limited to Report First Half, 2023 Results on Aug 14, 2023 China Regenerative Medicine International Limited announced that they will report first half, 2023 results on Aug 14, 2023 New Risk • Jul 18
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Hong Kong stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Profit margins are more than 30% lower than last year (2.1% net profit margin). Market cap is less than US$100m (HK$222.6m market cap, or US$28.5m). Announcement • Jun 07
China Regenerative Medicine International Limited, Annual General Meeting, Jun 29, 2023 China Regenerative Medicine International Limited, Annual General Meeting, Jun 29, 2023, at 10:30 China Standard Time. Location: Suite 2310-2318, Miramar Tower 132 Nathan Road, Tsim Sha Tsui Kowloon Hong Kong Agenda: To receive, consider and adopt the audited consolidated financial statements and the reports of the directors of the Company and the auditors of the Company for the year ended 31 December 2022; to re-elect Mr. Wang Chuang as an executive Director; to re-elect Ms. Huo Chunyu as an independent non-executive Director; to authorise the board of Directors to fix the remuneration of Directors; to re-appoint McM (HK) CPA Limited as the auditors of the Company and to authorise the board of Directors to fix their remuneration; and to consider other matters. Reported Earnings • May 17
First quarter 2023 earnings released: EPS: HK$0 (vs HK$0 in 1Q 2022) First quarter 2023 results: EPS: HK$0 (in line with 1Q 2022). Revenue: HK$54.1m (up 4.1% from 1Q 2022). Net income: HK$1.57m (up 40% from 1Q 2022). Profit margin: 2.9% (up from 2.2% in 1Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 123% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings. Announcement • May 04
China Regenerative Medicine International Limited to Report Q1, 2023 Results on May 15, 2023 China Regenerative Medicine International Limited announced that they will report Q1, 2023 results on May 15, 2023 Reported Earnings • Apr 12
Full year 2022 earnings released: EPS: HK$0.002 (vs HK$0.018 in FY 2021) Full year 2022 results: EPS: HK$0.002 (down from HK$0.018 in FY 2021). Revenue: HK$231.6m (down 18% from FY 2021). Net income: HK$4.56m (down 91% from FY 2021). Profit margin: 2.0% (down from 18% in FY 2021). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 116% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings. Reported Earnings • Nov 16
Third quarter 2022 earnings released: EPS: HK$0.003 (vs HK$0.001 in 3Q 2021) Third quarter 2022 results: EPS: HK$0.003 (up from HK$0.001 in 3Q 2021). Revenue: HK$76.9m (down 9.2% from 3Q 2021). Net income: HK$8.33m (up 139% from 3Q 2021). Profit margin: 11% (up from 4.1% in 3Q 2021). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 125% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings. Board Change • Nov 16
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. CEO, Executive Chairman & Compliance Officer Chuang Wang is the most experienced director on the board, commencing their role in 2019. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 13
Third quarter 2022 earnings released: EPS: HK$0.003 (vs HK$0.001 in 3Q 2021) Third quarter 2022 results: EPS: HK$0.003 (up from HK$0.001 in 3Q 2021). Revenue: HK$76.9m (down 9.2% from 3Q 2021). Net income: HK$8.33m (up 139% from 3Q 2021). Profit margin: 11% (up from 4.1% in 3Q 2021). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 125% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Announcement • Nov 02
China Regenerative Medicine International Limited to Report Nine Months, 2022 Results on Nov 11, 2022 China Regenerative Medicine International Limited announced that they will report nine months, 2022 results on Nov 11, 2022 Recent Insider Transactions • Sep 18
Key Executive recently bought HK$458k worth of stock On the 15th of September, Chuang Wang bought around 3m shares on-market at roughly HK$0.17 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth HK$511k. Chuang has been a buyer over the last 12 months, purchasing a net total of HK$1.5m worth in shares. Recent Insider Transactions • Sep 09
Key Executive recently bought HK$511k worth of stock On the 5th of September, Chuang Wang bought around 3m shares on-market at roughly HK$0.16 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Chuang's only on-market trade for the last 12 months. Announcement • Aug 03
China Regenerative Medicine International Limited to Report First Half, 2022 Results on Aug 12, 2022 China Regenerative Medicine International Limited announced that they will report first half, 2022 results on Aug 12, 2022 Announcement • Jun 07
China Regenerative Medicine International Limited, Annual General Meeting, Jun 29, 2022 China Regenerative Medicine International Limited, Annual General Meeting, Jun 29, 2022, at 10:30 China Standard Time. Location: Suite 2310-2318, Miramar Tower, 132 Nathan Road Tsim Sha Tsiu Kowloon Hong Kong Agenda: To receive and consider the audited consolidated financial statements and the reports of the directors and the auditors of the Company for the year ended 31 December 2021; to re-elect Mr. Tsang Ho Yin as non-executive Director; to re-elect Dr. Liu Ming as independent non-executive Director; to re-elect Mr. Leung Man Fai as independent non-executive Director; to authorise the board of directors to fix the remuneration of the directors; to re-appoint Messrs. McM (HK) CPA Limited as auditor of the Company and to authorise the board of directors to fix their remuneration; to grant a general mandate to the directors of the Company to allot, issue and deal with additional shares of the Company not exceeding 20% of the total number of its issued Shares as at the date of passing of this resolution; and to transact other business. Reported Earnings • May 16
First quarter 2022 earnings released: EPS: HK$0 (vs HK$0.001 in 1Q 2021) First quarter 2022 results: EPS: HK$0 (down from HK$0.001 in 1Q 2021). Revenue: HK$51.9m (up 27% from 1Q 2021). Net income: HK$1.12m (down 68% from 1Q 2021). Profit margin: 2.2% (down from 8.6% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 111% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. Announcement • May 05
China Regenerative Medicine International Limited to Report Q1, 2022 Results on May 13, 2022 China Regenerative Medicine International Limited announced that they will report Q1, 2022 results on May 13, 2022 Board Change • Apr 27
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. CEO, Executive Chairman & Compliance Officer Chuang Wang is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Announcement • Apr 23
China Regenerative Medicine International Limited to Report Fiscal Year 2021 Results on Apr 27, 2022 China Regenerative Medicine International Limited announced that they will report fiscal year 2021 results on Apr 27, 2022 Reported Earnings • Apr 03
Full year 2021 earnings released: EPS: HK$0.02 (vs HK$0.16 loss in FY 2020) Full year 2021 results: EPS: HK$0.02 (up from HK$0.16 loss in FY 2020). Revenue: HK$282.9m (up 53% from FY 2020). Net income: HK$51.8m (up HK$306.9m from FY 2020). Profit margin: 18% (up from net loss in FY 2020). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 99% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings. Board Change • Jan 02
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. CEO, Executive Chairman & Compliance Officer Chuang Wang is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • Nov 15
Third quarter 2021 earnings released: EPS HK$0.001 (vs HK$0.012 loss in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: HK$84.7m (up 32% from 3Q 2020). Net income: HK$3.50m (up HK$25.2m from 3Q 2020). Profit margin: 4.1% (up from net loss in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 76% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings. Executive Departure • Sep 07
Company Secretary Pak Chung Lee has left the company On the 1st of September, Pak Chung Lee's tenure as Company Secretary ended after 2.0 years in the role. We don't have any record of a personal shareholding under Pak Chung's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 2.92 years. Reported Earnings • Aug 18
Second quarter 2021 earnings released: EPS HK$0.009 (vs HK$0.001 loss in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: HK$74.3m (up 53% from 2Q 2020). Net income: HK$24.5m (up HK$26.0m from 2Q 2020). Profit margin: 33% (up from net loss in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has fallen by 50% per year, which means it is significantly lagging earnings. Reported Earnings • May 16
First quarter 2021 earnings released: EPS HK$0.001 (vs HK$0.017 loss in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: HK$41.0m (up HK$36.3m from 1Q 2020). Net income: HK$3.54m (up HK$18.6m from 1Q 2020). Profit margin: 8.6% (up from net loss in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 49% per year, which means it is significantly lagging earnings. Reported Earnings • Apr 02
Full year 2020 earnings released: HK$0.18 loss per share (vs HK$0.45 loss in FY 2019) The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: HK$185.3m (up 286% from FY 2019). Net loss: HK$255.1m (loss narrowed 35% from FY 2019). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings. Announcement • Mar 10
China Regenerative Medicine International Limited to Report Fiscal Year 2020 Results on Mar 19, 2021 China Regenerative Medicine International Limited announced that they will report fiscal year 2020 results on Mar 19, 2021 Recent Insider Transactions • Jan 10
Key Executive recently bought HK$303k worth of stock On the 7th of January, Chuang Wang bought around 740k shares on-market at roughly HK$0.41 per share. This was the largest purchase by an insider in the last 3 months. This was Chuang's only on-market trade for the last 12 months. Announcement • Dec 30
China Regenerative Medicine International Limited Announces Management Changes The board of directors of China Regenerative Medicine International Limited announced that with effect from 29 December 2020, Mr. Qiu Bin ("Mr. Qiu"), has tendered his resignation as (i) an execute Director; (ii) the authorized representative of the Company (the "Authorized Representative") under Rule 5.24 of the Rules Governing the Listing of Securities on the GEM (the "GEM Listing Rules") of The Stock Exchange of Hong Kong Limited (the "Stock Exchange"); and (iii) the compliance officer for the purpose of Rule 5.19 of the GEM Listing Rules (the "Compliance Officer") with effect from 29 December 2020 due to his decision to focus his time and effort on his other business. Following the resignation of Mr. Qiu, the Board further announces that Mr. Wang Chuang, the chairman of the Board, the chief executive officer of the Company and an executive Director, has be appointed as the Authorized Representative and the Compliance Officer with effect from 29 December 2020. The Board who announces that Mr. Wu Weiliang ("Mr. Wu") has tendered his resignation as a non-executive Director with effect from 29 December 2020 to devote more time and attention to his personal businesses. Mr. Wu has confirmed that (i) there is no disagreement between him and the Board; and (ii) there are no matters that need to be brought to the attention of the Stock Exchange or the Shareholders in relation to his resignation. Is New 90 Day High Low • Dec 14
New 90-day high: HK$0.62 The company is up 225% from its price of HK$0.19 on 15 September 2020. The Hong Kong market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 7.0% over the same period. Recent Insider Transactions • Dec 05
Insider recently sold HK$8.0m worth of stock On the 2nd of December, Xiaokai Mao sold around 16m shares on-market at roughly HK$0.51 per share. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought HK$15m more than they sold in the last 12 months. Recent Insider Transactions • Nov 25
Insider recently sold HK$3.4m worth of stock On the 20th of November, Xiaokai Mao sold around 10m shares on-market at roughly HK$0.34 per share. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought HK$34m more than they sold in the last 12 months. Is New 90 Day High Low • Nov 19
New 90-day high: HK$0.29 The company is up 7.0% from its price of HK$0.28 on 21 August 2020. The Hong Kong market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 14% over the same period. Reported Earnings • Nov 12
Third quarter 2020 earnings released: HK$0.01 loss per share The company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: HK$64.1m (up 393% from 3Q 2019). Net loss: HK$21.7m (loss narrowed 2.3% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has fallen by 62% per year, which means it is performing significantly worse than earnings. Announcement • Oct 28
China Regenerative Medicine International Limited to Report Nine Months, 2020 Results on Nov 11, 2020 China Regenerative Medicine International Limited announced that they will report nine months, 2020 results on Nov 11, 2020 Announcement • Jul 10
China Regenerative Medicine International Limited Announces CEO Changes China Regenerative Medicine International Limited announced the resignation of Mr. Wang Xuejun as a chief executive officer of the Company effect from July 9, 2020, due to his decision to focus his time and effort on his other business. Following the resignation of Mr. Wang, the Board further announces that Mr. Wang Chuang be appointed as the Chief Executive officer with effect from 9 July 2020. Mr. Wang Chuang, aged 40, was appointed as an executive Director and chairman of the Board with effect from 18 October 2019. He was accredited as a grade 1 health management professional by the Hubei Provincial Department of Human Resources and Social Security of China in May 2016 and a psychological consultant by the Ministry of Human Resources and Social Security of China in March 2019. 
